Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. / Hansen, Iben Onsberg; Sørensen, Anders Lindholm; Hasselbalch, Hans Carl.
I: European Journal of Haematology, Bind 98, Nr. 1, 2017, s. 75-84.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms
AU - Hansen, Iben Onsberg
AU - Sørensen, Anders Lindholm
AU - Hasselbalch, Hans Carl
N1 - © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2017
Y1 - 2017
N2 - OBJECTIVE: In an era of controversy in regard to 'hydroxyurea-leukaemogenicity' and when interferon-alfa2 (IFN) is being revived in the treatment of Philadelphia-negative myeloproliferative neoplasms (MPNs), we aim in this single-centre observational study to describe the frequencies of second malignancies in a cohort of MPN patients treated with hydroxyurea (HU) or IFN monotherapy or the combination of these agents.PATIENTS AND METHODS: Records of a MPN cohort of 196 patients were reviewed, and a retrospective analysis was performed on 90 patients treated with HU, 38 patients treated with IFN and 68 patients treated with both IFN and HU. Logistic regression was used to compare frequencies in second malignancies.RESULTS: Patients treated with HU had a significantly higher risk of developing all second malignancies compared with patients treated with IFN [HU vs. IFN: OR of 4.01 (95%CI: 1.12-14.27, P-value: 0.023) and HU-IFN vs. IFN: OR 5.58 (95%CI: 1.55-20.15, P-value: 0.004)].CONCLUSION: We have found an increased risk of second malignancies in MPN patients treated with HU compared with patients treated with IFN.
AB - OBJECTIVE: In an era of controversy in regard to 'hydroxyurea-leukaemogenicity' and when interferon-alfa2 (IFN) is being revived in the treatment of Philadelphia-negative myeloproliferative neoplasms (MPNs), we aim in this single-centre observational study to describe the frequencies of second malignancies in a cohort of MPN patients treated with hydroxyurea (HU) or IFN monotherapy or the combination of these agents.PATIENTS AND METHODS: Records of a MPN cohort of 196 patients were reviewed, and a retrospective analysis was performed on 90 patients treated with HU, 38 patients treated with IFN and 68 patients treated with both IFN and HU. Logistic regression was used to compare frequencies in second malignancies.RESULTS: Patients treated with HU had a significantly higher risk of developing all second malignancies compared with patients treated with IFN [HU vs. IFN: OR of 4.01 (95%CI: 1.12-14.27, P-value: 0.023) and HU-IFN vs. IFN: OR 5.58 (95%CI: 1.55-20.15, P-value: 0.004)].CONCLUSION: We have found an increased risk of second malignancies in MPN patients treated with HU compared with patients treated with IFN.
KW - Adult
KW - Age of Onset
KW - Aged
KW - Aged, 80 and over
KW - Comorbidity
KW - Female
KW - Humans
KW - Hydroxyurea/therapeutic use
KW - Interferon-alpha/therapeutic use
KW - Male
KW - Middle Aged
KW - Myeloproliferative Disorders/diagnosis
KW - Neoplasms, Second Primary/diagnosis
KW - Odds Ratio
KW - Retrospective Studies
KW - Young Adult
U2 - 10.1111/ejh.12787
DO - 10.1111/ejh.12787
M3 - Journal article
C2 - 27471124
VL - 98
SP - 75
EP - 84
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 1
ER -
ID: 194916743